Clinical Trials
21 trialsNCT05582499 2026-05-28
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT06797635 2026-05-20
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07320508 2026-05-12
EIC-SNACC
Eye & ENT Hospital of Fudan University
Phase 2 Recruiting
NCT04771871 2026-05-07
TARMAC
University College Hospital, Ibadan
Phase 2 Recruiting
NCT06291064 2026-02-17
TARMAC
University of Chicago
Phase 2 Recruiting
NCT06107673 2025-12-11
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT07016399 2025-10-30
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT04138719 2025-09-11
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT05900206 2025-09-02
ARIADNE
Karolinska University Hospital
Phase 2 Recruiting
NCT06500208 2025-06-26
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT06860529 2025-06-23
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT06964906 2025-05-11
NeoHunter
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06140966 2025-04-16
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT05024734 2025-03-11
GAIN INST
Hospital Centre Biel/Bienne
Phase 2 Recruiting
NCT06705127 2024-11-26
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06389006 2024-05-23
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06227117 2024-03-19
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT05978648 2023-11-30
SMA-BC-002
Sun Yat-sen University
Phase 2 Recruiting
NCT05447702 2023-05-22
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
West China Hospital
Phase 2 Recruiting
NCT03025477 2021-02-11
CHIMOVIP
Groupe Hospitalier Diaconesses Croix Saint-Simon
Phase 2 Recruiting
NCT04437160 2020-06-18
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
ChineseAMS
Phase 2 Recruiting